PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
1769944-4	1991	However, the TEM-1 and TEM-2 producers were resistant in disc tests to ampicillin/sulbactam and amoxycillin/clavulanic acid, and showed intermediate susceptibility to ticarcillin/clavulanic acid.	sultamicillin	71-91	hypothetical protein	Escherichia coli	13-18
1646771-2	1991	With TEM 1-producing E. coli, a correlation between specific beta-lactamase activity and the MIC of piperacillin and ampicillin-sulbactam was observed.	sultamicillin	117-137	hypothetical protein	Escherichia coli	5-10
33952829-0	2021	Dosing Optimization of Ampicillin-Sulbactam Based on Cystatin C in Elderly Patients with Pneumonia.	sultamicillin	23-43	cystatin C	Homo sapiens	53-63
6094422-0	1984	Sultamicillin (CP-49, 952): evaluation of two dosage schedules in urinary infection.	sultamicillin	0-13	beaded filament structural protein 2	Homo sapiens	15-20
33952829-8	2021	Serum cystatin-c concentration is an ideal index to optimize ampicillin-sulbactam antimicrobial therapy in elderly patients with pneumonia.	sultamicillin	61-81	cystatin C	Homo sapiens	6-16
30455244-0	2019	Role of TEM-1 beta-Lactamase in the Predominance of Ampicillin-Sulbactam-Nonsusceptible Escherichia coli in Japan.	sultamicillin	52-72	TEM-1 beta-lactamase	Escherichia coli	8-28
30455244-7	2019	All 45 transconjugants from 96 donors with TEM-1 had higher ampicillin-sulbactam MICs (4 to 96 mg/liter) than the recipient (2 mg/liter).	sultamicillin	60-80	hypothetical protein	Escherichia coli	43-48
30455244-8	2019	In donors with only TEM-1, TEM-1 activity correlated with the 50% inhibitory concentration of sulbactam and ampicillin-sulbactam MICs.	sultamicillin	108-128	hypothetical protein	Escherichia coli	20-25
30455244-8	2019	In donors with only TEM-1, TEM-1 activity correlated with the 50% inhibitory concentration of sulbactam and ampicillin-sulbactam MICs.	sultamicillin	108-128	hypothetical protein	Escherichia coli	27-32
30455244-10	2019	The reduced permeation was partly attributable to deficient outer membrane proteins, which were observed in 57% of the ampicillin-sulbactam-nonsusceptible isolates with only TEM-1 and a wild-type promoter.	sultamicillin	119-139	hypothetical protein	Escherichia coli	174-179
10440070-1	1999	Bacteria possessing TEM-1-like beta-lactamases are generally regarded as susceptible to ampicillin-sulbactam (SAM), while those harboring OXA-1 enzymes are considered resistant.	sultamicillin	88-108	CD248 molecule	Homo sapiens	20-25
26962817-9	2016	The only independent variables associated with colonization by MDR GNB and ESBL-producing organisms and multiple colonization were, respectively, the days of NICU stay (odds ratio [OR] 1.041), the days of exposure to ampicillin-sulbactam (OR 1.040), and the days of formula feeding (OR 1.031).	sultamicillin	217-237	EsbL	Escherichia coli	75-79
26482308-6	2016	Susceptibilities of ESBL-positive isolates to ampicillin-sulbactam (<10%) were low, whereas susceptibilities to ciprofloxacin (0% to 54.6%) and levofloxacin (0% to 63.6%) varied substantially.	sultamicillin	46-66	EsbL	Escherichia coli	20-24
8851602-0	1996	Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.	sultamicillin	24-44	TEM-1 beta-lactamase	Escherichia coli	53-73
8851602-1	1996	The clinical outcome in patients treated with ampicillin-sulbactam may not always be predictable by disc susceptibility testing or with the MIC as determined with a constant level (4 micrograms/ml) of the beta-lactamase inhibitor (MIC1).	sultamicillin	46-66	growth differentiation factor 15	Homo sapiens	231-235
18611721-0	1996	Efficacy and safety of sultamicillin (750 mg bid) compared with amoxycillin/clavulanate (625 mg tid) in patients with umcomplicated urinary tract infections.	sultamicillin	23-36	BH3 interacting domain death agonist	Homo sapiens	45-48
18611721-6	1996	Sultamicillin is an efficacious treatment for acute urinary tract infections, like AMX/CLA.	sultamicillin	0-13	selectin P ligand	Homo sapiens	87-90